Taking a drug candidate from a validated target to an IND filing is one of the most operationally complex challenges in early-stage drug development. The process spans target validation, antigen preparation, animal immunization, antibody screening, lead optimization, developability assessment, and a full suite of preclinical studies, each stage dependent on the last, and each capable of derailing a program if executed in isolation. For biotech teams working under capital constraints and investor timelines, fragmented CRO relationships are not just inconvenient; they are a structural risk.
Nona Biosciences was built to eliminate that risk. The I to I® (Idea toward IND) framework integrates every stage of antibody discovery and preclinical development under a single, consultative partnership, one that begins at target ideation and ends at IND filing.
Why Fragmented Discovery Fails Modern Antibody Programs
The traditional CRO model operates on a handoff basis: one vendor handles immunization, another runs screening, a third manages lead optimization, and a fourth conducts preclinical pharmacology. Each transition introduces timeline risk, data discontinuity, and accountability gaps. When a program stalls in complex modalities, programs frequently identify that the root cause across multiple vendors is slow and expensive.
This fragmentation problem is compounded by the increasing complexity of the modalities that dominate today’s pipeline. Bispecific antibodies are now the most requested modality across the industry, with ADCs, bispecific ADCs, in vivo CAR-T, and multi-specific T-cell engagers following closely. These formats demand tight coordination between discovery and engineering teams. A bispecific ADC, for example, requires both arms to bind distinct targets while ensuring the payload activates only within the tumor microenvironment, a design challenge that cannot be solved by sequential, siloed vendors.
The market has also shifted decisively toward fully human antibody platforms. Humanization costs and timelines are no longer acceptable when fully human alternatives exist. Harbour Mice®, Nona’s proprietary transgenic platform, generates fully human monoclonal antibodies in both the conventional H2L2 (two heavy, two light chain) format and the heavy chain-only antibody (HCAb) format.
The HCAb format is particularly relevant for next-generation modalities: single-domain VH antibodies derived from HCAb technology are gaining traction in bispecific ADCs and fragment-based ADCs precisely because their compact size enables titration of toxic payloads and, in molecules under approximately 40 kDa, can achieve renal clearance. This is not a theoretical advantage; it is a design requirement for the ADC formats the market is actively building toward.
The Integrated Discovery Architecture: From Antigen to IND
Nona’s integrated workflow is structured to maintain scientific continuity across every stage, with each phase informing the next rather than operating independently.
Antigen Preparation and Immunization
Program quality is established at immunization, not rescued downstream. Nona advocates for a two-month immunization protocol to ensure high-quality immune responses and reliable antibody titers. Compressing this to a three-week protocol, a shortcut some providers offer, produces unknown titers and introduces downstream uncertainty that cannot be corrected at the screening stage. The Harbour Mice® platform is continuously optimized to maintain strong immune responses and high antibody titers upon immunization, ensuring a diverse, high-affinity starting pool for every program.
High-Throughput Screening and Lead Generation
Following immunization, Nona deploys Single B-Cell (SBC) cloning, a process that takes approximately one month rather than traditional hybridoma methods, which require two to three months. This is not simply a timeline compression; SBC cloning preserves the native pairing of heavy and light chains and provides direct access to fully human sequences without the sequence drift associated with hybridoma culture. The screening platform is designed to handle complex targets and difficult modalities, with customizable workflows for programs that standard phage display cannot address.
Lead Optimization, Engineering, and Developability
Antibody leads that clear initial screening enter a structured optimization and engineering phase covering affinity maturation, format conversion (including bispecific and multi-specific engineering), and developability assessment. Lead selection is supported by Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization), trained on large-scale proprietary HCAb libraries (>9M sequences) and target-specific experimental binding data derived from Harbour Mice® discovery programs.
Developability is evaluated early, not as a final checkpoint before IND, because structural liabilities identified late translate directly into re-engineering cycles and timeline delays. Fully human VH domains sourced from naturally selected HCAbs reduce the need for extensive re-engineering and minimize immunogenicity risks, accelerating the path through IND-enabling studies.
Preclinical Pharmacology and IND Preparation
The final stages of the I to I® workflow cover pharmacological evaluation and the preclinical package required for IND filing. Because the same team that designed the molecule is executing the preclinical work, the scientific rationale for every design decision is preserved and documented, a material advantage when preparing regulatory submissions.
IP Ownership, Freedom to Operate, and the Partnership Model
For biotech companies, IP ownership is not a negotiating point; it is a program requirement. Royalty structures and post-IND milestone fees attached to platform access can encumber exit plans, complicate licensing deals, and reduce the attractiveness of an asset to acquirers. Nona’s business model grants clients complete IP ownership and full Freedom to Operate. There are no royalties on discovered antibodies.
This stands in direct contrast to models where platform access comes with ongoing financial obligations that follow the molecule through clinical development and commercialization. For VC-backed biotechs and academic spin-outs building toward an exit, the downstream cost structure of a discovery partnership is as important as the upfront service quality.
Beyond IP terms, the consultative model Nona operates under is structurally different from execution-focused CROs. Where large-scale service providers follow predefined SOPs and present clients with a menu of options, Nona’s team engages at the project design level, defining strategy, adapting workflows to the specific biology of the target, and functioning as a scientific partner rather than a vendor executing a pre-written plan. This distinction matters most in complex programs where the path from target to IND is not linear and requires real-time scientific judgment.
Timeline commitments are treated as binding obligations, not estimates. Speed-to-IND is a priority, but not at the expense of a quality decision that determines whether a molecule is viable at the end of the program. The goal is strict adherence to an agreed timeline, not an artificially compressed one that produces a weaker asset.
Building the Next Generation of Antibody Therapeutics
The modalities that will define the next decade of drug development, bispecific ADCs, multi-specific T-cell engagers, in vivo CAR-T, VH-based BBB-crossing therapeutics for neurological indications, all share a common requirement: they need a discovery partner with both the platform depth to generate the right starting molecules and the engineering capability to build them into clinical candidates.
Partnerships with organizations including Pfizer, Umoja, and Valink reflect the level of scientific rigor and platform reliability that partners apply when selecting discovery collaborators for high-stakes programs. Learn more about Nona’s work in antibody-drug conjugate development.
For teams evaluating their Target-to-IND strategy, the decision is not simply about which CRO to use at each stage. It is whether the program’s scientific and commercial objectives are best served by a fragmented vendor model or by an integrated partner with the platform, IP structure, and consultative depth to take a target all the way to the clinic.
Ready to map your target to an IND filing? Connect with Nona Biosciences’ scientific team to review your program requirements and explore how the I to I® framework applies to your specific modality and timeline.
-
Crescioli S. et al., Antibodies to watch in 2025, mAbs, 2024. Link
-
Klein C. et al., The present and future of bispecific antibodies for cancer therapy, Nature Reviews Drug Discovery, 2024. Link
-
Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link
-
Sivalingam G.N. et al., Single B cell technologies for monoclonal antibody discovery, Trends in Immunology, 2021. Link
-
Zhang W. et al., Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics, Antibody Therapeutics, 2022. Link
-
Raybould M.I.J. et al., Predicting antibody developability profiles through early stage discovery screening, mAbs, 2020. Link
-
Medina Pérez V.M. et al., Single-domain antibodies as antibody-drug conjugates: from promise to practice — a systematic review, Cancers, 2024. Link
-
Yan X. et al., Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate, Pharmacological Research, 2024. Link
-
Tsuchikama K. et al., Exploring the next generation of antibody-drug conjugates, Nature Reviews Clinical Oncology, 2024. Link
